No Data
No Data
Laimei Pharmaceutical (300006.SZ): Net loss of 4.575,300 yuan in the first quarter
On April 23, Ge Longhui Pharmaceutical (300006.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 181 million yuan, a year-on-year decrease of 20.09%; net profit attributable to shareholders of listed companies - 4,5753 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 7.4337 million yuan; basic earnings per share - 0.0043 yuan.
Lemei Pharmaceutical (300006.SZ): Currently, tadalafil tablets sold as agents by the company account for a small share of revenue
Gelonghui, April 18 | Lemei Pharmaceutical (300006.SZ) said on the investor interactive platform that currently the company sells tadalafil tablets as agents account for a small share of revenue. Currently, the company is mainly focusing on core advantage products, actively expanding the market of its flagship product Canalin in clinical fields such as thyroid, broadening the generic drug market, actively introducing new products and technologies, etc., and increasing the company's revenue level.
Lamy Pharmaceuticals (300006.SZ): Kangdesai's CUD005 injection received a notice of approval for drug clinical trials
Gelonghui, March 28, 丨 Lemei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd. participated in a self-developed macrophage CUD005 injection (“CUD005 injection”) of Sichuan Kangdesai Medical Technology Co., Ltd. (“CUD005 injection”), a self-developed macrophage cell CUD005 injection (“CUD005 injection” for short) to treat decompensated liver cirrhosis, obtained implied approval for drug clinical trials and obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. Cirrhosis of the liver is a common chronic progressive tissue damage liver disease. The causes include long-term alcohol abuse, obesity, metabolic disorders,
Laimei Pharmaceutical (300006.SZ) subsidiary's endoscopic products obtained medical device registration certificate
Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Hainan Laimei Medical Devices Co., Ltd. (hereinafter referred to as “Laimei Medical Devices”), a holding subsidiary of the company, received two “medical device registration certificates” issued by the Hainan Drug Administration. The products are: “electromechanical endoscopic image processor” and “disposable electronic bronchial imaging catheter”. The single-use electronic bronchial imaging catheter and electronic endoscopic image processor, which obtained the “Medical Device Registration Certificate” this time, is an endoscopic product developed by Laimei Medical Devices. This product can directly observe patient images, which is beneficial
Laimei Pharmaceutical (300006.SZ): net loss of 8.9273 million yuan in 2023
Gelonghui, March 22丨Laimei Pharmaceutical (300006.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 896 million yuan, an increase of 1.24% over the previous year; net profit attributable to shareholders of listed companies was -8.9273 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -59.333 million yuan; and basic earnings per share was -0.0085 yuan.
Laimei Pharmaceutical (300006.SZ): The ban on 244 million restricted shares will be lifted on March 22
On March 19, Ge Longhui Pharmaceutical (300006.SZ) announced an indicative announcement on the listing and circulation of restricted shares issued to specific targets. The shares that have been lifted are the company's shares issued to specific targets in 2021. The total number of shareholders applying to lift sales restrictions is 3. The number of shares that have been lifted this time is 244 million shares, accounting for 23.08% of the company's total share capital. The listing and circulation date for the shares whose sales restrictions have been lifted is March 22, 2024 (Friday).
No Data